Growth & profitability
- Revenue has grown 12.5% per year over the past 1 years.
- Operating margin has expanded, at -268.4% in the latest year.
2 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $5M | -$27M | -4.1% | -268.4% | — | — | $7M |
| 2024 | $4M | -$21M | -2.6% | -312.3% | — | — | $96000 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $1M | -$8M | 23.9% | -392.3% | -$4M | — | $121000 |
| Dec '25 | $1M | -$4M | 40.7% | -297.6% | — | — | $7M |
| Sep '25 | $1M | -$10M | -11.0% | -293.8% | — | — | $3M |
| Jun '25 | — | -$7M | — | — | — | — | $410000 |
| Mar '25 | $620000 | -$6M | -57.7% | -523.5% | -$2M | — | — |
| Dec '24 | $836000 | -$9M | 16.3% | -427.3% | — | — | $96000 |
| Sep '24 | $881000 | -$6M | -76.4% | -504.4% | — | — | — |
| Jun '24 | — | -$4M | — | — | — | — | — |
| Mar '24 | — | -$2M | — | — | — | — | — |
How the market has priced PMI against its own fundamentals since 2025-08 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 1 years, Picard Medical, Inc.'s revenue has grown 12.5% per year. These are computed facts, not advice.
As of FY2025, Picard Medical, Inc. reported — of total debt against $7M of cash.
In FY2025, gross margin was -4.1%, operating margin -268.4%, and net margin -546.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.